Annals of Clinical Oncology最新文献

{"title":"Cell Surface Lipoprotein Lipase Enzyme as A Prognostic Indicator in B-Cell Chronic Lymphocytic Leukemia","authors":"Caleb J. Yelton, Elaine P. Kuhn, William B. Kinlaw, F. Lansigan","doi":"10.31487/j.aco.2023.01.02","DOIUrl":"https://doi.org/10.31487/j.aco.2023.01.02","url":null,"abstract":"Lipoprotein lipase (LPL) has emerged as a distinct prognostic marker for chronic lymphocytic leukemia (CLL), a heterogeneous disease with a similar heterogeneity in life expectancy. While many prior studies have focused on tumor expression of LPL mRNA, LPL surface protein expression has been less robustly studied as a prognostic marker. A novel antibody developed at Geisel School of Medicine at Dartmouth has been previously utilized in immunohistochemistry assays of breast and prostate cancer. With this study we aimed to use this antibody as a flow cytometry marker of surface LPL expression correlated with overall survival and time to first treatment. Of the 19 patients studied, our data show that LPL surface protein expression as measured by flow cytometry trended toward a protective effect on overall survival and overall better prognosis.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133184142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Factors for Cervical Cancer in FIGO-Stages IA-IIB in a 10-Year Period in the Region of Uppsala, Sweden: Population Cohort Study","authors":"I. Skirnisdottir, Karina Varasteh","doi":"10.31487/j.aco.2022.02.03","DOIUrl":"https://doi.org/10.31487/j.aco.2022.02.03","url":null,"abstract":"Background: The incidence of cervical cancer in Sweden decreased to 8/100,000 in the year 2011 but has from 2014 increased to 11/100,000. The noted increase was, mainly observed in FIGO-stages IA-IB, where patients usually are asymptomatic and detected in screening. \u0000Materials and Methods: The study population consisted of 253 patients with cervical carcinoma in FIGO-stages IA-IIB. The patients were referred to the Department of Gynecology at the Akademiska University Hospital in Uppsala for decision of treatment from 2008 to 2017. \u0000Results: Clinical and pathological features of cervical carcinoma were compared according to the subtypes: squamous cell carcinoma (n=150), adenocarcinoma (n=74) and adeno-squamous cancer (n=29). Other rare histological types (n = 6) were excluded. Finally, 207 (82%) out of the 253 referred patients, had primary surgical treatment and 29 (14%) patients had additional oncological treatment. The remaining 46 patients (18%) received primary oncological treatment. In the present study 45 (17.8%) developed recurrent disease. Prognostic factors for disease-free survival in Cox-regression analysis were stage (IA versus IIB) (p = 0.000) and histopathologic subtype (p = 0.009). In a survival analysis the disease-free survival differed between the histological subtypes; 62 % for squamous cell cancer in cervix, 48 % for adenocarcinoma, and 32 % for adeno-squamous cancer (Chi-square = 6,221; p = 0,045)). Logistic regression analysis including treatment details, showed no other predictive factors for recurrent disease. \u0000Conclusion: The results from this study suggest that prognostic factors for disease-free survival are FIGO-stage (IA –IIB) and histopathology, but not tumor grade, age or choice of treatment.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114946658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Older Patients and the Epidemiological Change after COVID-19 Pandemic. The Simplicity of the Complexity Management and the Personalization in Cancer Care","authors":"G. Colloca, A. Bellieni, D. Fusco, F. Benvenuto, S. Bracci, E. Villani, B. D. Capua, F. Marazzi, L. Tagliaferri, L. Balducci, S. Monfardini, V. Valentini","doi":"10.31487/j.aco.2021.01.01","DOIUrl":"https://doi.org/10.31487/j.aco.2021.01.01","url":null,"abstract":"The SARS-CoV-2 pandemic has led us to imagine the current scenario as something terrible, disastrous, but temporary. However, history teaches us that an event of this magnitude can only evolve towards “new” normality, a new equilibrium, but it will only be reached through a transition that will last over the years. In this scenario, the term “frailty”, which is known to few, has become common. The need for healthcare that, alongside high specialization, focuses on the complexity of the individual is increasingly intense. Geriatric oncology probably represents the clearest example of how much the current scenario has impacted the health and social fields, as it involves frail adults with cancer. How to draw the future?","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132442131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Lower Fixed Dose Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer Patients in a Lower-Middle Income Country: Jordan Experience","authors":"Salah Abbasi, Layla S Abbasi, Adnan Almallah, Nedal F Al-Rawashdeh","doi":"10.31487/j.aco.2022.02.01","DOIUrl":"https://doi.org/10.31487/j.aco.2022.02.01","url":null,"abstract":"Background: Pembrolizumab was approved as first line treatment of advanced non-small cell lung cancer (NSCLC) at standard dose of 200mg every 3 weeks. We aim to assess the efficacy of a lower fixed dose of 100mg and review the Jordanian experience in first line setting. \u0000Methods: We conducted a retrospective study of 88 NSCLC patients, including 27 who received low fixed dose pembrolizumab (Pem100) and 61 received standard fixed dose (Pem200) from September 2016 to February 2022.\u0000Results: Objective response rate was (48.8%), including (5.6%) with complete response, and (43.2%) with partial response. The median progression free survival (PFS) and median overall survival (OS) for this Jordanian population were consistent with published clinical trials; 8.00 months (95% CI, 7.19 to 8.80) and 17.48 months (95 CI, 15.53 to 19.44), respectively. The PFS and OS were not statistically different between the Pem100 and Pem200 groups (8.00 vs. 8.00 months, p=0.73, and 17.02 vs 17.60 months, p=0.66, respectively). PFS and OS were significantly affected by the programmed cell death ligand (PD-L1) tumor proportion score (TPS) (12.40 vs. 8.00 vs. 5.80 months, p<0.001, and 22.70 vs. 16.47 vs. 12.71 months, p<0.001, in TPS ≥ 50% vs. TPS 1-49% vs. TPS < 1%, respectively). OS was not statistically different according to age, gender, histology, or smoking status.\u0000Conclusion: Lower fixed dose pembrolizumab (100mg 3-weekly) appears to be effective in first line NSCLC. A randomized trial should be done to investigate this low dose with significant cost reduction potential.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"27 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120879396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Radiation Referral Rates for Metastatic Bone Disease Within the Veteran’s Health Administration and at an Academic Center","authors":"K. Gundle, Sarah M Hanna, Andrew R Summers, Travis C Philipp, Reid F Thompson, James B Hayden, Yee Cheen Doung","doi":"10.31487/j.aco.2022.01.01","DOIUrl":"https://doi.org/10.31487/j.aco.2022.01.01","url":null,"abstract":"Background: External beam radiation therapy is an important aspect of multidisciplinary care for patients with metastatic bone disease. Referral to radiation oncology is within the control of the orthopaedic surgeon and has the potential to serve as a quality benchmark. \u0000Methods: This is a retrospective cohort study. Patients with metastatic disease of the femur who underwent prophylactic femoral stabilization or fixation of a pathologic femur fracture from 2010-2015 at a single academic medical center or within the Veterans Health Administration (VHA) were included. A total of 950 VHA patients and 130 academic medical center patients were enrolled. The main outcome was the proportion of patients receiving a referral to radiation oncology by six weeks after the date of surgery. Results are presented for each institution and are stratified by type of procedure (prophylactic stabilization versus pathologic fixation). The study further evaluates regional differences within the VHA.\u0000Results: The majority of patients received a referral for radiation after prophylactic stabilization (VHA: 290/361 patients [80% 95% CI: 76% - 84%]; academic medical center: 81/89 patients [91%, 95% CI: 85%, 97%]). The proportion referred was higher at the academic medical center (odds ratio [OR]: 2.5, 95% CI: [1.15, 5.36], P =0.027). After fracture fixation, 428/589 (73%, 95% CI: [69%, 77%]) of VHA patients and 30/41 (73%, 95% CI [59%, 87%]) of patients at the academic medical center received a referral to radiation. Receiving a referral was not associated with healthcare system (OR: 1.0; 95% CI: [0.50, 2.10])). Within the VHA, the proportion of patients referred varied by geographic location (Pearson’s chi-squared test, P =0.004 for prophylactic stabilization and P <0.001 for pathologic fixation). \u0000Conclusion: Referral rates at both institutions were moderate to high. The observed regional variation within the VHA highlights the importance of establishing quality benchmarks.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116714937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response Evaluation with Dynamic FDG PET/CT during the Primary Systemic Therapy of Breast Cancer - A Case Report","authors":"Kornélia Kajáry, Z. Lengyel, A. Tőkés, J. Kulka, M. Dank, Tímea Tőkés","doi":"10.31487/j.aco.2021.01.02","DOIUrl":"https://doi.org/10.31487/j.aco.2021.01.02","url":null,"abstract":"18-fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET) and mainly combined with \u0000computed tomography (CT), abbreviated as FDG PET/CT is a useful and accurate tool for staging and \u0000restaging in locally advanced breast cancer. In daily practice static images are prepared during the PET/CT \u0000examinations. However, despite the success of static PET and PET/CT imaging, the role of precise \u0000quantification of FDG-uptake – measured by dynamic acquisition – is ambiguous in the staging and \u0000management of different malignancies. In this case report, we described our experience with staging, interim \u0000and restaging dynamic PET/CT examinations of a woman suffering from breast cancer. Based on the \u0000described case we concluded that dynamic PET/CT is suitable for accurate quantification of FDG-uptake in \u0000primary breast tumors. However, performing dynamic PET/CT examinations is time-consuming, therefore, \u0000it is important to define the group of patients where their use is with the most favourable benefit/risk ratio. \u0000Furthermore, using of interim PET/CT scan is recommended in cases with clinically controversial baseline \u0000tests. Based on literature in vivo biomarkers of the dynamic PET/CT are predictive of more favourable tumor \u0000response and longer disease-free survival, as confirmed by our own results.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128599294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appearance of 4 Degree Rash While Treating Advanced Lung Cancer with Icotinib – Whether to Stop the Drug: A Case Report","authors":"Jie Lin, L. Lv, Lifeng Jiang, Wenhui Zhang, Xinyan Lu, Tingting Li","doi":"10.31487/j.aco.2020.03.02","DOIUrl":"https://doi.org/10.31487/j.aco.2020.03.02","url":null,"abstract":"Skin and skin adnexa toxicities are the most common side effects associated with epidermal growth factor\u0000receptor tyrosine kinase inhibitors (EGFR-TKIs). Previous research showed that the rash appeared, and the\u0000severity of EGFR-TKIs may be a marker of clinical benefit. In this context, we report a 75-year-old man\u0000with advanced lung cancer who on receiving icotinib developed severe adverse reactions, 4 degree rash\u0000(NCI-CTC AE version 4.0 common toxicity grading standards grade), and refused to stop taking the drug;\u0000but with the anti-infection and symptomatic nursing, the patient recovered, the rash disappeared, and the\u0000patient received a better prognosis. Thus, we would like to emphasize the importance of deciding whether\u0000to stop the drug when patients developed adverse reactions of 3-4 degree rash.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125146783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathology and Diagnosis of Mantle Cell Lymphoma","authors":"E. Elhassadi","doi":"10.31487/j.aco.2020.02.02","DOIUrl":"https://doi.org/10.31487/j.aco.2020.02.02","url":null,"abstract":"Mantle Cell Lymphoma (MCL) is a rare type of B-cell non-Hodgkin lymphoma (NHL), characterised by an\u0000aggressive clinical course and a poor prognosis that remains incurable for the majority of patients. Cyclin\u0000D1 overexpression, which results from t(11; 14)(q13; q32), is the pathogenic hallmark in MCL disease and\u0000causing cell cycle disruption. MCL has been categorized based on lymphoid malignancies in the WHO\u0000update into two significant subgroups, nodal and leukemic non-nodal MCL; each type has a particular\u0000clinical presentation and distinct molecular features. SOX11 is overexpressed in nodal MCL subtype, while\u0000the leukemic non-nodal sub-type is associated with SOX11 negativity. MCL has a wide range of differential\u0000diagnoses, including other types of low-grade lymphoma, most notably chronic lymphocytic leukaemia\u0000(CLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and lymphoblastic lymphoma (LBL).\u0000Therefore, accurate histological biopsy diagnosis is paramount in this rare subtype of NHL. MCL has a\u0000distinctive clinical presentation and particular morphological and immunophenotypic features with specific\u0000cytogenetic abnormalities. The recent advances in molecular and cytogenetic analysis have improved the\u0000accuracy of MCL diagnosis and enhanced disease prognosis. Furthermore, B cell receptor inhibitors have\u0000revolutionized MCL treatment. Therefore, an accurate diagnosis of MCL is very important since this may\u0000require an aggressive and novel targeted therapy.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115768340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Clinical Management of Neuroendocrine Tumor of the Breast: Report of Six Cases and Systematic Review of Existing Literature","authors":"A. Bottini, A. Luca, A. Sagona, C. Tinterri, E. Marrazzo, E. Barbieri, F. Frusone, G. Puliani, G. Canavese, W. Gatzemeier","doi":"10.31487/j.aco.2020.01.02","DOIUrl":"https://doi.org/10.31487/j.aco.2020.01.02","url":null,"abstract":"Introduction: Neuroendocrine neoplasm of the breast (bNENs) are considered a rare disease, even if in\u0000WHO data they represent about 2-5 % of all breast cancer. The last WHO classification includes: welldifferentiated neuroendocrine tumor (bNET), neuroendocrine carcinoma (NEC) and invasive carcinoma\u0000with neuroendocrine differentiation. The current knowledge on clinical management of bNENs is poor and\u0000patients are usually treated according to non-endocrine tumor components guidelines.\u0000Materials and Methods: We presented our experience of six cases of bNENs. Moreover, we conducted a\u0000systematic review of published data on diagnosis, treatment and outcome of this kind of tumors.\u0000Results: bNENS usually presented as palpable breast masses, classically appearing as irregular hypoechoic\u0000lesions at US examination and as hyperdense masses at mammography. Usually pre-operative tumor biopsy\u0000is not able to recognize the neuroendocrine components and the final diagnosis is performed only on\u0000definitive histopathological assessment. The most frequent subtype seems to be neuroendocrine carcinoma\u0000and synaptophysin is positive in most specimens. Treatment strategies, including surgical treatment,\u0000radiotherapy and medical treatment are nowadays based on current non-endocrine breast cancer guidelines,\u0000independently from neuroendocrine components, even if some studies have proposed the use of somatostatin\u0000analogues for bNET and cisplatin-etoposide for NEC. Prognosis of all bNENs, especially of poorly\u0000differentiated neoplasia, seems worse compared to non-neuroendocrine breast cancer and stage and\u0000morphology seem the best predictor of tumor outcome.\u0000Conclusions: We provide an algorithm for clinical management of bNETs, basing on available data. More\u0000studies are necessary for confirming the best treatment strategy for these patients, in order to improve\u0000clinical outcome","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"144 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123472782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is TP53 mutation screening in Mantle Cell Lymphoma (MCL) ready for prime time?","authors":"E. Elhassadi","doi":"10.31487/j.aco.2019.03.05","DOIUrl":"https://doi.org/10.31487/j.aco.2019.03.05","url":null,"abstract":"Mantle cell lymphoma (MCL) is a rare incurable subtype of B-cell lymphoma characterized by t(11;14)(q13;q32)-driven over expression of cyclin D1 [1]. MCL is associated with the highest degree of genomic instability of the B cell malignancies, and TP53 mutation in particular confers a dismal prognosis in MCL with a reported incidence of 15-20 % (blastoid=29% vs Classical= 6%) [2, 3]. TP53 mutation status is the only independent molecular marker that was able to improve the prognostic value of the Mantle cell lymphoma International Prognostic Index (MIPI) [4]. MCL Patients with a TP53 mutation were significantly less likely to achieve a CR after first-line treatment and associated early relapse. The current standard of care, Chemo-immunotherapy with high-dose Cytarabine followed by autologous stem cell transplant (ASCT) (in eligible patient), although most patients prove ineligible, have failed to overcome the poor prognostic impact of TP53 disruption [4]. Ibrutinib and Venetoclax (ABT-199) are two of the most active agents in the treatment of MCL, they have acceptable toxicity profiles and mainly are used in relapse setting. Pre-clinical models predict synergy between these novel drugs in combination. Patients who received Ibrutinib after an initial relapse had significantly longer PFS and OS than patients who received Ibrutinib after successive relapses probably related to selective advantage of resistant clone expansion [5]. In MCL, the attention should be move to the upfront treatment setting using these target therapies in high risk disease (TP53 mutated) and elderly patients whom un-fit for chemo-immunotherapy approach and phase III clinical trial eagerly awaited to support this approach. Likewise, in chronic lymphocytic leukaemia (CLL) incorporating TP53 mutation screening in routine practice prior commencing therapy is paramount in the era of novel effective therapies. Younger MCL patients with this genetic alteration should be considered for specific treatment using inhibitors for BCR, BCL2, TP53-independent pathways, the Anti-CD20 monoclonal antibodies either alone or in combination followed by allogeneic stem cell transplantation in the upfront setting. Chemo-free approach also to be considered for un-fit patients early in the disease course. Fit un-mutated TP53 MCL Patients should be treated with chemo-immunotherapy with ASCT consolidation if eligible and anti CD20 monoclonal antibody maintenance therapy.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129505847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}